Despite Struggles, Bank of America Continues to Back John Paulson

Equities Editors Desk  |

Bank of America (BAC) hosted a much-anticipated conference call with famed investor John Paulson on Tuesday to address his hedge fund's alarmingly poor performance in recent years. While the call was described by participants as cordial, many had expected a more heated conversation given that Paulson's two flagship funds have been significantly underperforming against the broader market.

Paulson's managed assets have twindled from a peak of $38 billion to just south of $20 billion this year. In 2011, the Paulson Advantage fund was down 36 percent while the Paulson Advantage Plus was down 52 percent. The funds have lost 13 percent and 18 percent, respectively, this year, according to WSJ. Despite his struggles, Paulson is still regarded as one of the most prominent money managers on Wall Street due to his phenomenal success during the market crash in 2007.

A large portion of the funds' struggles have been attributed to his excessive bullishness on gold. Paulson is the largest holder of the SPDR Gold Shares (GLD) with 22 million shares, and has positions in several gold miners including Allied Nevada Gold (ANV), Anglogold Ashanti (AU), and Barrick Gold (ABX).

Last week, Citigroup (C) announced that it would no longer invest with Paulson, withdrawing $410 million in assets. Morgan Stanley (MS) has also put Paulson's fund on watch, restricting new investments into the fund. Bank of America, however, seemed to be confident that Paulson will be able to right the ship, and even offered praise at times during the call.

Going forward, the hedge fund manager still appears bullish on gold's prospects, as well as the growth opportunities in casino stocks like Caesars Entertainment (CZR) and MGM Resorts International (MGM) as a play on Macau.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
CRRR:CA Crombie Real Estate Investment Trust Subscription Rcpt 03/12/2014 n/a n/a n/a 0
C Citigroup Inc. 65.73 -0.86 -1.29 32,809,241 Trade
MS Morgan Stanley 44.52 -0.59 -1.31 15,095,320 Trade
ABX Barrick Gold Corporation 13.34 0.25 1.91 29,114,802 Trade
BAC Bank of America Corporation 27.02 -0.36 -1.31 102,392,522 Trade
MGM MGM Resorts International 25.32 -0.78 -2.99 11,379,617 Trade
CZR Caesars Entertainment Corporation 9.03 -0.46 -4.85 28,199,313 Trade
AU AngloGold Ashanti Limited 9.98 0.22 2.25 3,104,138 Trade

Comments

Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.